Marcus Niemeyer
Research Subjects
Research Interests
Marcus Niemeyer has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Ditlef Bucher
Novo Nordisk A/S
2 shared publicationsMarianne Rye Hansen
Novo Nordisk A/S
2 shared publicationsNiels Bjerrum Thomsen
Novo Nordisk A/S
2 shared publicationsHans Hemmingsen
Novo Nordisk A/S, Hillerød, Denmark
1 shared publicationJakob Oest Wielandt
Novo Nordisk A/S, Hillerød, Denmark
1 shared publication
Latest Publications
- Open Access
- 1 December 2011
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 13 (12) , 1207-1211
A Prefilled Insulin Pen with a Novel Injection Mechanism and a Lower Injection Force than Other Prefilled Insulin Pens
Background: FlexTouch ® (Novo Nordisk A/S, Bagsvaerd, Denmark) is a new prefilled insulin pen for people with diabetes, with a novel injection mechanism and no push-button extension at any dose setting. This study compared the injection force of FlexTouch with that of SoloStar ® (sanofi-aventis, Paris, France) and KwikPen ® (Eli Lilly & Co., Indianapolis, IN). Methods: Injection force was measured with the manufacturers' recommended needle attached to each pen (NovoFine ® [Novo Nordisk] 32-gauge tip extra thin wall 6 mm needle for FlexTouch and BD [Franklin Lakes, NJ] MicroFine™ 31-gauge 5 mm needle for SoloStar and KwikPen) during injection of the maximum dose (60 IU for KwikPen and 80 IU for FlexTouch and SoloStar). Injection was performed at three different constant push-button speeds. Results: FlexTouch had a significantly ( P <0.0001) lower injection force than SoloStar and KwikPen at all injection speeds. The mean±SD injection force of FlexTouch was 5.1±0.5 N. At 4, 6, and 8 mm/s push-button speeds, the injection force of SoloStar was 13.5±2.1, 19.1±1.9, and 26.9±2.4 N, respectively, and the injection force of KwikPen was 14.5±1.9, 20.9±1.4, and 28.2±1.4 N, respectively. Conclusions: The injection mechanism of FlexTouch means that insulin injection is driven by a torque spring and not the thumb pressure of the user. This results in a 62–82% lower injection force with FlexTouch than other prefilled insulin pens.
- 1 December 2011
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 13 (12) , 1207-1211
Open AccessA Prefilled Insulin Pen with a Novel Injection Mechanism and a Lower Injection Force than Other Prefilled Insulin Pens
Background: FlexTouch ® (Novo Nordisk A/S, Bagsvaerd, Denmark) is a new prefilled insulin pen for people with diabetes, with a novel injection mechanism and no push-button extension at any dose setting. This study compared the injection force of FlexTouch with that of SoloStar ® (sanofi-aventis, Paris, France) and KwikPen ® (Eli Lilly & Co., Indianapolis, IN). Methods: Injection force was measured with the manufacturers' recommended needle attached to each pen (NovoFine ® [Novo Nordisk] 32-gauge tip extra thin wall 6 mm needle for FlexTouch and BD [Franklin Lakes, NJ] MicroFine™ 31-gauge 5 mm needle for SoloStar and KwikPen) during injection of the maximum dose (60 IU for KwikPen and 80 IU for FlexTouch and SoloStar). Injection was performed at three different constant push-button speeds. Results: FlexTouch had a significantly ( P <0.0001) lower injection force than SoloStar and KwikPen at all injection speeds. The mean±SD injection force of FlexTouch was 5.1±0.5 N. At 4, 6, and 8 mm/s push-button speeds, the injection force of SoloStar was 13.5±2.1, 19.1±1.9, and 26.9±2.4 N, respectively, and the injection force of KwikPen was 14.5±1.9, 20.9±1.4, and 28.2±1.4 N, respectively. Conclusions: The injection mechanism of FlexTouch means that insulin injection is driven by a torque spring and not the thumb pressure of the user. This results in a 62–82% lower injection force with FlexTouch than other prefilled insulin pens.
- Open Access
- 1 September 2011
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 5 (5) , 1195-1199
FlexTouch: A Prefilled Insulin Pen with a Novel Injection Mechanism with Consistent High Accuracy at Low- (1 U), Medium- (40 U), and High- (80 U) Dose Settings
FlexTouch® is the only prefilled insulin pen that utilizes an easy touch button that does not extend at any dose in place of a push-button extension. Rigorous testing has shown that the new FlexTouch pen accurately and consistently delivers insulin doses. This study assessed dose accuracy of FlexTouch, KwikPen®, and SoloSTAR®. Dose accuracy for minimum, medium, and maximum doses of each pen type (1, 40, and 80 U for FlexTouch and SoloSTAR and 1, 30, and 60 U for KwikPen) was assessed. FlexTouch delivered all doses consistently, as demonstrated by low standard deviations. FlexTouch showed similar accuracy to KwikPen at 1 U and to SoloSTAR at 40 and 80 U. However, FlexTouch was significantly more accurate at delivering 1 U of insulin than SoloSTAR (p < .0001). This study demonstrates that FlexTouch, a new prefilled pen, delivers insulin accurately and consistently at low, medium, and high doses. In addition, FlexTouch is currently the only prefilled pen that has a push button that does not extend at any dose, making FlexTouch easier to use than other pens.
- 1 September 2011
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 5 (5) , 1195-1199
Open AccessFlexTouch: A Prefilled Insulin Pen with a Novel Injection Mechanism with Consistent High Accuracy at Low- (1 U), Medium- (40 U), and High- (80 U) Dose Settings
FlexTouch® is the only prefilled insulin pen that utilizes an easy touch button that does not extend at any dose in place of a push-button extension. Rigorous testing has shown that the new FlexTouch pen accurately and consistently delivers insulin doses. This study assessed dose accuracy of FlexTouch, KwikPen®, and SoloSTAR®. Dose accuracy for minimum, medium, and maximum doses of each pen type (1, 40, and 80 U for FlexTouch and SoloSTAR and 1, 30, and 60 U for KwikPen) was assessed. FlexTouch delivered all doses consistently, as demonstrated by low standard deviations. FlexTouch showed similar accuracy to KwikPen at 1 U and to SoloSTAR at 40 and 80 U. However, FlexTouch was significantly more accurate at delivering 1 U of insulin than SoloSTAR (p < .0001). This study demonstrates that FlexTouch, a new prefilled pen, delivers insulin accurately and consistently at low, medium, and high doses. In addition, FlexTouch is currently the only prefilled pen that has a push button that does not extend at any dose, making FlexTouch easier to use than other pens.